Introduction
Transplantation is a life-saving treatment for end-stage organ failure, but for the majority of recipients, ongoing graft function relies on long-term maintenance immunosuppression, with the attendant complications of cancer, opportunistic infection, and metabolic derangement (1) . Achievement of alloantigen-specific tolerance would alleviate the burden of immunosuppressive therapy, improving both graft and patient outcomes.
The liver is a tolerogenic environment. Spontaneous liver transplant tolerance is observed in both small and large animal models (2) (3) (4) , and up to 20% of clinical liver transplant recipients may be successfully weaned from all immunosuppression (5) . Primary viral infections of hepatocytes frequently persist (6) (7) (8) , while tolerance of various transgene products expressed in the liver following transduction of hepatocytes with viral vectors has also been documented (9) (10) (11) (12) (13) . Recombinant vectors based on the Adeno-associated virus (AAV) are promising candidates for liver-directed gene transfer -not only for the treatment of monogenic liver diseases (14, 15) , but also for the induction of systemic, antigen-specific tolerance (16) , an application that may be of great benefit to transplant recipients. AAV vectors have an excellent safety profile and are currently being evaluated in a range of clinical trials (17) . Recent advances in AAV vector biology have yielded vectors with greatly increased transduction efficiency for human hepatocytes (18) . We have previously Adeno-associated viral vector-mediated (AAV-mediated) expression of allogeneic major histocompatibility complex class I (MHC class I) in recipient liver induces donor-specific tolerance in mouse skin transplant models in which a class I allele (H-2K b or H-2K d ) is mismatched between donor and recipient. Tolerance can be induced in mice primed by prior rejection of a donor-strain skin graft, as well as in naive recipients. Allogeneic MHC class I may be recognized by recipient T cells as an intact molecule (direct recognition) or may be processed and presented as an allogeneic peptide in the context of self-MHC (indirect recognition). The relative contributions of direct and indirect allorecognition to tolerance induction in this setting are unknown. Using hepatocytespecific AAV vectors encoding WT allogeneic MHC class I molecules, or class I molecules containing a point mutation (D227K) that impedes direct recognition of intact allogeneic MHC class I by CD8 + T cells without hampering the presentation of processed peptides derived from allogeneic MHC class I, we show here that tolerance induction depends upon recognition of intact MHC class I. Indirect recognition alone yielded a modest prolongation of subsequent skin graft survival, attributable to the generation of CD4 + Tregs, but it was not sufficient to induce tolerance.
demonstrated that AAV-mediated expression of donor major histocompatibility complex class I (MHC class I; H-2Kᵇ) in MHC-mismatched recipient hepatocytes induces donor-specific tolerance in a mouse skin transplant model. Tolerance can be induced in mice primed by prior rejection of a donor-strain skin graft, as well as in naive recipients (19) . The ability to overcome preexisting immunity is particularly relevant to the clinical setting, where heterologous immunity presents a barrier to transplant tolerance induction (20) . To progress toward clinical translation of this strategy, it is imperative to determine whether tolerance induction can be generalized to other mismatched alleles and MHC backgrounds, and to understand more about the underlying mechanisms; in the process, we may also come to understand more about allorecognition in spontaneous liver transplant tolerance. Allogeneic MHC class I may be recognized by recipient T cells as an intact molecule on the surface of the antigen-presenting cell (APC) (direct recognition) or may be processed and presented as allogeneic peptide fragments in the context of self-MHC molecules (indirect recognition), reviewed in ref. 21 . Antigen presentation by several populations of liver-resident cells including hepatocytes (22) , Kupffer cells (12) , DCs (23) (24) (25) (26) , and sinusoidal endothelial cells (27) has been reported to induce tolerance. Hepatic stellate cells may themselves act as APC (28, 29) or may regulate the outcome of antigen presentation by other cell types (30, 31) . The structure of the hepatic microcirculation facilitates interactions between circulating naive T cells and hepatocytes (32) , promoting tolerance induction. Recognition of intact allogeneic MHC class I by alloreactive CD8 + T cells depends upon engagement of the CD8 coreceptor by residues present in the acidic loop of the α3 domain of MHC class I (33, 34) . Accordingly, recognition of an intact allogeneic MHC class I transgene product can be impeded by introducing a point mutation from a conserved aspartic acid to lysine at position 227 of the class I heavy chain (D227K) (35, 36) . The D227K mutation does not impair presentation of processed MHC class I peptides. In this study, we have utilized AAV vectors encoding the D227K mutant or WT allogeneic MHC class I molecules (H-2K  b or H-2K   d ) to determine the relative contributions of direct and indirect allorecognition to transplant tolerance induction.
Results

AAV-mediated gene transfer of H-2K
d to C57BL/6 recipient hepatocytes induces tolerance to H-2K d -bearing skin grafts. We have previously shown that expression of H-2Kᵇ in the recipient liver induces donor-specific tolerance in a mouse skin transplant model where H-2K b is mismatched between the donor and the B10.BR (H-2 k ) host. Tolerance could be induced in mice in which T cells were primed by prior rejection of a donor-strain skin graft, as well as in naive recipients (19) .
To evaluate whether this protocol could eventually be used to induce donor-specific tolerance in a clinical setting, it was critical to demonstrate that tolerance induction was generalizable to additional allogeneic MHC class I transgenes and recipient haplotypes. We treated C57BL/6 (H- -transduced mice received skin grafts from B6.Kd donors on d7 after inoculation. Dose-dependent survival prolongation was observed, culminating in indefinite survival of all grafts at a dose of 5 × 10 11 vgc, compared with a median survival time (MST) of 15 days in untreated recipients and 19 days in recipients inoculated with a third-party control vector encoding H-2K k (P = 0.0008; Figure 1A) . A modest acceleration of rejection tempo was observed in mice primed by rejection of a B6.Kd graft, compared with unprimed recipients of grafts from the same donor (MST 17 days vs. 22.5 days, P = 0.03, Figure 1B ). Indefinite survival of secondary grafts was obtained in recipients that had been primed 30 days prior to inoculation with 5 × 10 11 vgc AAV-K d , whereas graft survival in primed recipients was not prolonged by 5 × 10 10 vgc AAV-K d (MST 21.5 days compared with 24 days in untreated primed recipients, P = 0.228, Figure 1C ). A heavy cellular infiltrate was present in rejecting grafts, accompanied by complete loss of the graft epithelium ( Figure 1D ). In contrast, the histological appearances of long-surviving B6.Kd allografts to mice transduced with AAV-K d resembled those of syngeneic transplants (Figure 1 , E-G), and persistent expression of the allogeneic MHC class I was detectable (Figure 1, H , suggesting that expression of allogeneic MHC class I in recipient hepatocytes is a broadly applicable strategy for transplant tolerance induction.
The D227K mutation does not affect membrane expression of allogeneic MHC class I molecules. To determine the contribution of intact vs. processed donor class I in tolerance induction, we generated AAV-Kᵇ-D227K and Kᵈ-D227K vectors (Supplemental Figure 1 , B and C) in which a point mutation in the α3 domain of the encoded class I heavy chains abrogates CD8 binding to MHC class I (33) (34) (35) (36) , thus impeding direct allorecognition. WT and mutant (D227K) MHC class I molecules were expressed at comparable levels on the surface of transduced hepatocytes on d7 following a dose of 5 × 10 11 vgc of the relevant vectors ( Figure 2 ). The D227K mutation disrupts recognition of intact allogeneic MHC class I, without affecting recognition of processed class I. To test the effects of the D227K mutation on the direct and indirect allorecognition pathways, -D227K was detected (9.5% ± 3.8% on d10, against 0.95% ± 0.52% on d2, P = 0.014), suggesting that some recognition of processed -D227K-treated mice (P = 0.04). This experiment was performed twice with 3-4 mice/group for each experiment. Representative dot plots are shown. Box shows minimum to maximum, with a line at the mean. Data are described as mean ± SEM and were analyzed using an unpaired t test. compared with uninjected recipients), but again, tolerance was not induced (P = 0.0005, compared with recipients inoculated with AAV-K d ; Figure 6B ).
IFN-γ production by alloreactive responder cells is reduced by recognition of intact but not processed MHC class I.
Recipient anti-donor alloresponses were measured using IFN-γ ELISpot. C57BL/6 mice were primed against H-2K d using a B6.Kd skin graft, and were then rested for 30-35 days after rejection to allow development of a memory response. The number of responder cells producing IFN-γ upon exposure to H- TH6. The nondepleting anti-FR4 antibody 12A5 does not compete for epitope binding against TH6 (Supplemental Figure 6A ) and was used for FR4 detection. TH6 treatment significantly reduced the numbers of CD4 + FoxP3 + T cells in both peripheral blood (6.98 × 10 4 ± 9.72 × 10 3 vs. 1.09 × 10 4 ± 5.38 × 10 3 , P = 0.008, Figure 8 , A and C) and spleen (1.03 × 10 6 ± 2.19 × 10 4 vs. 7.86 × 10 5 ± 5.17 × 10 4 , P = 0.01, Figure 8 , B and D) while having no effect upon CD8 + T cells (Supplemental Figure 6 , B and C). A substantial proportion of CD4 + FoxP3 + T cells express both CD25 and FR4. As expected, the number of these cells in peripheral blood and spleen declined significantly following TH6 administration (Figure 8,  C and D) . While the reduction of the FR4 + fraction in spleen was accompanied by an overall decrease in CD4 + FoxP3 + T cell numbers, there was also an increase in the proportion of CD25 + FR4 -cells upon TH6 treatment ( Figure 8B ), suggesting that FR4 engagement may have resulted in shedding or internalization of this receptor on some cells, as previously observed (39) . The survival prolongation of 178.3 skin grafts in B10.BR mice inoculated with Kᵇ-D227K was abrogated when the recipients were treated with anti-FR4 (clone TH6). MST was reduced from 27 days in AAV-K b -D227K-transduced mice receiving an isotype-control antibody to 17.5 days in mice receiving anti-FR4 (P = 0.042, Figure 9B ). Skin graft 
Discussion
In this study, we have demonstrated that tolerance of allogeneic MHC class I can be induced in several different donor-recipient strain combinations by AAV-mediated gene transfer to hepatocytes and that recognition of intact donor MHC class I molecules by alloreactive CD8 + T cells is a requirement for tolerance induction. In accordance with data from a number of other studies (19, (40) (41) (42) , tolerance induction is dependent upon the expression of high levels of the donor MHC class I in recipient hepatocytes. The vector dose required to achieve tolerance was 5 × 10 11 vgc, 10-fold higher than the dose of AAV-K b required to achieve indefinite survival in the majority of naive B10.BR mice in an earlier study (19) , despite uniform strong expression of K d on the surface of all hepatocytes across the liver lobule at the lower dose of 5 × 10 10 vgc. The reasons for this difference are unclear but may relate to a higher precursor frequency of K d -reactive T cells in C57BL/6 recipients compared with the frequency of K b -reactive cells in B10.BR hosts, or to more rapid turnover of hepatocytes in C57BL/6, leading to the loss of episomal AAV vector genomes. Gene transfer to recipient liver using AAV vectors is an emerging therapy for the induction of antigen-specific tolerance (16), which could be of significant benefit in the setting of clinical organ and tissue transplantation. A broad array of mismatched MHC antigens may be encountered by recipients, and so establishing the generalizability of this approach beyond the strain combination where it was initially demonstrated is a prerequisite for further progress toward clinical translation. Understanding the mechanisms that contribute to tolerance induction is essential to facilitate refinement and optimization of tolerance-induction protocols. Moreover, insights gained from the study of responses to allogeneic MHC transgenes expressed in the liver may enhance our understanding of related phenomena such as spontaneous liver transplant tolerance. Multiple pathways for donor antigen presentation may be active following transduction of recipient hepatocytes with donor MHC class I. Intact allogeneic class I expressed on the hepatocyte surface may be directly recognized by recipient CD8 + T cells. Semidirect recognition may follow the transfer of intact donor class I from hepatocytes to the surface of other cell types (43) (44) (45) . Peptides derived from the allogeneic class I protein may be presented to self-restricted CD8 + T cells associated with MHC class I of the recipient haplotype (46) , either on hepatocytes (indirect recognition) or on other APC (cross-presentation). Cross-presentation in the liver is restricted to liver sinusoidal endothelial cells and some liver DC subsets (26, 27) , and in the absence of inflammation, it is generally associated with tolerance induction (27, (47) (48) (49) . Presentation of donor class I peptides by recipient MHC class II to recipient CD4 + T cells (indirect recognition) may also occur (50) . We took advantage of a point mutation that abrogates CD8 coreceptor binding and, thus, interferes with recognition of the intact donor MHC class I (35) -but does not prevent peptide processing and presentation -to examine the contributions of intact and processed MHC class I to transplant tolerance induction.
In both B10.BR and C57BL/6 strains, impairment of direct or semi-direct recognition of intact donor MHC class I by introduction of the D227K mutation prevented tolerance induction. Recognition of processed donor MHC class I alone yielded a modest survival prolongation in both strain combinations, attributable to the generation of CD4 + Tregs. However, depletion of Tregs in the presence of direct recognition of donor MHC class I did not alter graft survival, in contrast to several other models of tolerance induction following gene transfer to liver, where CD4 + Tregs are critical mediators of tolerance (9) (10) (11) (12) . Activation (and subsequent regulatory conversion) of CD4 + T cells by peptides derived from these cytosolic or secreted transgene products may form a more prominent component of the recipient immune response than in our model where the transgene product is an allogeneic MHC class I molecule expressed on the cell surface.
Reported outcomes of primary CD8 + T cell activation in liver in the presence of a moderate or large antigen load include deletion (by suicidal emperipolesis or apoptosis; refs. 51-53), exhaustion, and functional silencing (19, 41, 53) or the development of a regulatory phenotype (54) . CD8 + Tregs generated in response to AAV-mediated expression of H-2K d in hepatocytes were able to mediate acceptance of allogeneic pancreatic islet grafts following adoptive transfer into naive, immunocompetent recipients (54) . The fate of CD8 + T cells activated through direct recognition by allogeneic MHC (53, 54) . Whether this denotes exhaustion, regulatory potential, or any other aspect of T cell function has yet to be established for this model. IFN-γ production by both unfractionated and CD8-enriched splenocytes upon exposure to H-2K d -bearing stimulator cells was significantly reduced in mice inoculated with AAV-K d but not those treated with AAV-K d -D227K. While reduced ability to secrete IFN-γ upon stimulation is a hallmark of T cell exhaustion, it is also possible that many alloreactive CD8 + T cells have been deleted from the responding population and/ or that the actions of CD4 + and CD8 + Tregs may have contributed to this outcome. Moreover, while hepatocytes are certainly capable of activating naive CD8 + T cells, it is not certain whether or not CD8 + T cells may also be activated by other APC, consequent upon cell-to-cell transfer of intact allogeneic MHC from transduced hepatocytes, and what the significance of this might be. Unlike the findings of Le Guen et al. (54) , but in accordance with our previous observations (19) , tolerance to a single mismatched MHC antigen (H-2K d ) did not confer tolerance to a subsequent full haplotype mismatched skin graft from Dba/2 (H-2 d ) donors. In this respect, skin graft rejection may be more difficult to overcome than islet rejection, or the lower dose of AAV-K d vector used by Le Guen and colleagues (54) (1.2 × 10 12 vgc/kg compared with the dose of approximately 2 × 10 13 vgc/kg required to achieve skin graft tolerance in the current study) may have favored the emergence of a regulatory phenotype rather than deletion or silencing.
In conclusion, recognition of intact MHC class I by alloreactive CD8 + T cells is required for tolerance induction via liver-directed expression of donor MHC class I. Indirect recognition of class I allopeptides and generation of Tregs can produce a modest prolongation of class I-mismatched skin graft survival but does not induce tolerance. These findings have significant implications for the development of strategies to induce transplant tolerance in the clinic. Future approaches that might increase the generation of CD4 + Tregs while maintaining the potent induction of tolerance in alloreactive CD8 + T cell populations might include coadministration of soluble with surface-expressed MHC class I to increase uptake of the allogeneic MHC by class II-expressing recipient APC (12) . Alternatively, allogeneic MHC class I gene transfer to hepatocytes may be combined with regulatory cell infusion protocols, such as those evaluated under the auspices of the One study (55-57) and subsequent clinical trials. Conversely, the survival prolongation obtained through treatment of recipient mice with AAV-K b -D227K (MST 26 days, compared with 16 days in untransduced mice, P = 0.015) was maintained when the isotype control mAb was coadministered (MST 27 days; n = 3) but abolished when anti-FR4 was given (MST 17.5 days; n = 6; P = 0.0046). Boxes in C and D show minimum to maximum with a line at the mean. Data described as mean ± SEM, statistical analyses were performed using an unpaired t test; n = 3/group. (E and F) Survival of B6.Kd skin grafts to DEREG mice transduced with AAV-K d was not influenced by DT treatment. Conversely, B6.Kd skin graft survival in DEREG mice inoculated with AAV-K d -D227K was reduced from 27 to 18 days (P = 0.0046) when DT was coadministered, abrogating the survival prolongation due to expression of the K d -D227K transgene. n = 6/group; survival analysis was performed using the log-rank test. 
Methods
Mice
AAV vectors
The 1107-bp coding sequence of H-2K d was obtained from Dba/2 spleen complementary DNA (forward primer 5′ -AGA AGT GGG CAG CTG TGG -3′; reverse primer 5′ -CTC TGG TTG TAG TAT CTC TGT GC -3′). H-2K b was cloned as previously described (19) . H-2K d and H-2K b sequences incorporating the D227K mutation were created in silico and manufactured by GeneArt (Thermo Fisher Scientific). Each gene was then packaged into an AAV2/8 vector, purified, and quantitated as previously described (19, 62) .
Histology and immunostaining
Preparation of fresh frozen sections. OCT-embedded frozen tissue blocks were cut into 6 μm-thick sections (using a Shandon Cryotome E, Thermo Fisher Scientific). Sections were transferred to precoated glass slides (SuperFrost, Menzel-Glazer) and allowed to air dry for 1 hour at room temperature (RT), prior to fixation in acetone for 8 minutes at RT. When dry, acetone-fixed sections were stored at -80°C until further use.
IHC on frozen sections. Fresh frozen sections were thawed to RT for 15 minutes and then rehydrated by washing in tris-buffered saline (TBS). Tissue was encircled with a wax pen (Dako, catalog S2002). TBS with 20% normal mouse serum (NMS) (MilliporeSigma, catalog M5905) and 5% normal porcine serum (NPS) (Thermo Fisher Scientific, catalog 31890) was applied to the sections for 20 minutes to block nonspecific antibody binding. FITC-conjugated primary antibodies against H-2K d CD4, CD8α, F4/80, or B220 or the corresponding isotype controls (Supplemental Table 2 ) were diluted in TBS/5%NPS, applied to the sections, and incubated in a humidified chamber for 30 minutes at RT. Slides were then washed twice in TBS. The secondary antibody (Supplemental Table 2 ) at 5 ng/ml in TBST/NMS/NPS diluent was added to the sections, which were again incubated in a humidified chamber for 30 minutes at RT. After washing in TBS, color development was achieved using diaminobenzidine (DAB) substrate chromogen system (Dako, catalog K3468). Chromogen DAB was diluted in substrate to a concentration of 50 μl/ml, applied to the sections, and incubated in a humidified chamber for 2 minutes. Slides were counterstained in Mayer's hematoxylin solution (MilliporeSigma, catalog MHS16) for 2 minutes, air-dried for 24 hours, and coverslipped using 24 mm × 24 mm Deckgläser cover slips (Knittel Glass) and Fronine safety mount No.4 (Thermo Fisher Scientific, catalog FNNII068).
Processing and histochemical staining of paraffin-embedded tissue sections. Tissue processing and H&E staining were performed by the Histopathology Laboratory, Discipline of Pathology, Sydney Medical School. Briefly, formalin-fixed tissue was paraffin-embedded, dehydrated, cleared, and infiltrated with paraffin wax before 5 μm sections were cut onto on precoated glass slides (SuperFrost, Menzel-Glazer). Fresh paraffin-embedded sections were stored at 4°C until further use. Before staining, precut sections were gently warmed to RT. Slides were then soaked in 3 changes of histolene for 10 minutes each, followed by rehydration of sections in graded ethanol. Finally, sections were washed in 2 changes of dH 2 O for 3 minutes each. Once rehydrated, the sections were kept hydrated throughout the entire staining process and not allowed to dry out.
IHC on paraffin sections. Deparaffinized and rehydrated paraffin-embedded sections were microwaved (1100W, Panasonic) in citrate buffer (pH6) for 1 minute on 100% power and then for a further 20 minutes at 10% power for antigen retrieval. Slides were then cooled to RT and washed in TBS with 0.01% v/v Tween-20 (TBST; MilliporeSigma, catalog P1379). Tissue was encircled with a wax pen and then TBST with 20% normal goat serum (NGS) (Abcam, catalog ab156046) was applied to the sections for 20 minutes. The primary antibody against mouse Ly-6B.2 or relevant isotype control (Supplemental Table 2 ) was diluted in TBST with 1% NGS to a concentration of 10 μg/ml, applied to sections, and incubated in a humidified chamber for 1 hour at RT. Following incubation, slides were washed in 2 changes of TBST and then incubated with 3% H 2 O 2 /CH 3 OH solution for 5 minutes at 4°C to block endogenous peroxidase activity before further washing in TBST. Sections were incubated with the secondary antibody (Supplemental Table 2 ) and diluted in TBST/NGS in a humidified chamber for 1 hour. Slides were washed again in TBST, followed by visualization using the Vectastain ABC kit (Vector Laboratories, catalog PK-4000), according to the manufacturer's directions. Briefly, Solution A and B were diluted in TBST/NGS to a concentration of 5 μl/ml each, applied to the sections, and incubated in a humidified chamber for 30 minutes at RT. Color development with DAB, counterstaining, and coverslipping were performed as above.
Skin transplantation
All procedures were performed under inhalational anesthesia with isoflurane (Baxter, catalog AHN3637),1%-3%, in oxygen at 0.5-1 l/min. Tail skin was harvested by making a midline incision along the ventral aspect of the amputated tail. The skin was mobilized and separated from underlying connective tissue and then irrigated in sterile saline, flattened, and dissected to yield 6 x 1cm 2 grafts. Grafts were stored over ice, between saline-soaked gauze impregnated with ampicillin (Alphapharm), 3 mg/ml, until transplanted. Recipient mice received buprenorphine (Temgesic, Schering-Plough) (0.05 mg/kg, s.c.) for analgesia and 0.5 ml warmed normal saline s.c. for preoperative hydration. Temperature was maintained via a Physitemp TCAT-2DF Controller (Physitemp Instruments). The back and lateral thoracic regions were shaved with a scalpel blade from the cervical to the distal thoracic levels, and they were sterilized using Chlorhexidine 0.5% in ethanol 70% (Pfizer). Two graft beds were prepared and irrigated with sterile saline. Each mouse received both a syngeneic (R) and allogeneic (L) graft. Graft edges were secured with small amounts of cyanoacrylate tissue adhesive (Dermabond, Ethicon, catalog ANX12). A nonadhesive absorptive dressing was placed on top of the graft and secured with adhesive cloth bandage. A further 0.5 ml of warmed saline and prophylactic ampicillin (100 mg/kg) were administered s.c. prior to conclusion of the procedure. Skin grafts were deemed rejected when less than 20% of the graft remained. Some mice received a secondary skin graft following either rejection or long-term acceptance of the primary graft.
Tissue collection
At the termination of each experiment, tissue was collected under anesthesia. Blood was sampled via inferior vena cava (IVC) puncture, allowed to clot at RT for 60 minutes, and was then centrifuged at 1,000 g for 10 minutes before serum was withdrawn.
Liver was handled gently to avoid damage. The liver was divided into portions: one was formalin-fixed for 24 hours before paraffin-embedding and sectioning, and the second was embedded in OCT (Tissue-Tek, Sakura Finetec) and frozen in liquid N 2 vapor, prior to storage at -80°C.
Hepatocyte isolation
Midline laparotomy was performed under anaesthesia; the IVC was identified. A 22 G cannula was introduced distal to the renal bifurcation and secured using a 5-0 silk tie. Retrograde perfusion of the liver was achieved via the IVC cannula. The hepatic portal vein was transected to allow outflow of perfusate. The liver was sequentially perfused with the following solutions at a flow rate of 5 ml/min (administered using a Masterflex L/S 7528-30, Thermo Fisher Scientific); firstly with 25 ml of HBSS (Lonza, catalog 10-543F), then with 25 ml of HBSS with 0.5 mM EDTA (MilliporeSigma, catalog E6758), followed by 25 ml of HBSS, and finally with 25 ml of HBSS plus 5 mM CaCl 2 (calcium chloride, MilliporeSigma, catalog C5670) and 0.05% of collagenase IV (collagenase Type IV, Thermo Fisher Scientific, catalog 17104019). All solutions were warmed to 37°C. The gall bladder was removed and discarded. Lobes of the liver were collected, taking care to avoid damage, and transferred into a Petri dish containing RPMI 1640 (Lonza, catalog 12-702F) medium with 2% FCS (RPMI/FCS2) at 4°C and gently agitated to disperse the hepatocytes. The hepatocyte slurry was transferred to a 50 ml conical tube and washed with RPMI/FCS2 by centrifugation at 50 g for 3 minutes. The hepatocyte pellet was gently resuspended in 15 ml PBS (ambient temperature), and then 9 ml of isotonic Percoll PLUS (GE Healthcare Life Sciences, Australia) were added and mixed. The mixture was centrifuged at 500 g for 15 minutes at RT with the brake off. Debris and excess solution was aspirated from the tube, and the hepatocyte pellet was washed twice, as above. Viable hepatocytes were resuspended in RPMI + 10%FCS (RPMI/FCS10) and counted on a hemocytometer using Trypan Blue exclusion.
Leukocyte isolation from liver, spleen, and draining LN For liver leukocyte isolation, the IVC was cannulated as above. The liver was flushed with 20 ml of PBS at RT, with venting via a portal vein incision. Liver lobes were transferred onto a 100 μm cell strainer, gently pressed through and washed through with cold RMPI/FCS2, and then transferred into a 50 ml conical tube. The liver slurry was washed twice with 50 ml RPMI + 5% FCS (RPMI/FCS5) by centrifugation at 400 g for 10 minutes. The supernatant was decanted, and the cell pellet was then resuspended in 15 ml PBS (RT). Isotonic Percoll PLUS (9 ml)were added and mixed; tubes were centrifuged at 500 g for 15 minutes, with no brake. The supernatant was discarded, and the liver leucocytes were then washed once before being resuspended in 2 ml of red cell lysis solution and left to incubate for 2 minutes. Following this, the liver leucocytes were washed twice with RPMI/FCS5 before viable cells were counted, as above. The spleen was pressed through a 70 μm nylon mesh strainer into a 50 ml conical tube, and the strainer was rinsed with 50 ml cold RPMI/FCS5. The cells were spun at 400 g for 10 minutes. The supernatant was discarded, and cells were then incubated in 2 ml of red cell lysis buffer for 2 minutes at RT. The cells were washed and counted, as above. The liver draining (hepatic portal, para-aortic, and mesenteric) LNs were identified using 10× surgical magnification and excised. The nodes were ruptured through a 40 μm nylon mesh strainer and then prepared as for splenocytes, with the omission of the red cell lysis step.
splenocytes were incubated with a cocktail of antibody and detection beads, and they were then separated on the autoMACS Pro Separator (Miltenyi Biotec) using the "Depletes" program. The negative fraction containing CD8 + T cells was washed, counted, and subsequently used for ELISpot. The fraction of CD8 + T cells within the enriched splenocyte populations averaged 75% ± 3.8%, and CD4 + T cells were virtually undetectable following separation (Supplemental Figure 10) .
For prestimulation, 1 × 10 6 of stimulator and 1 × 10 6 responder splenocytes were suspended in 250 μl RPMI/FCS10 plus penicillin-streptomycin (Invitrogen, catalog 15140) in each well of a 96-well U-bottom plate (Corning, catalog 3788). They were cultured at 37°C + 5% CO 2 in a humidified incubator for 24 hours and then transferred into an antibody-coated polyvinylidene difluoride (PVDF) plate, serially diluted, and incubated for a further 16 hours. The plates were then developed, and the spots were counted using an AID iSpot plate reader as previously described (19) .
